Omeprazole Xeolas Pharmaceuticals (Omeprazole)

Omeprazole is a proton pump inhibitor indicated for several acid‑related conditions.

• Gastroesophageal reflux disease (GERD): reduces reflux symptoms and promotes healing of esophageal irritation.
• Peptic ulcer disease: facilitates ulcer healing by suppressing gastric acid secretion.
• NSAID‑induced gastric ulcer: protects the gastric mucosa in patients taking non‑steroidal anti‑inflammatory drugs.
• Helicobacter pylori eradication (in combination therapy): enhances the effectiveness of antibiotic regimens used to eradicate H. pylori.
• Zollinger‑Ellison syndrome: controls excessive gastric acid production associated with gastrin‑secreting tumors.

• Omeprazole irreversibly binds to the cysteine residues of the gastric H+/K+ ATPase pump located on the parietal cell membrane. This inhibition blocks the final step of acid secretion, leading to a sustained reduction in gastric acidity and allowing damaged mucosal tissue to heal.

Omeprazole is generally well tolerated, but adverse reactions can occur.

Common Side Effects

• Headache: mild to moderate intensity.
• Diarrhea: loose stools that may resolve with continued therapy.
• Abdominal pain: discomfort or cramping in the stomach area.
• Nausea: feeling of queasiness, often transient.
• Flatulence: increased intestinal gas.
• Constipation: reduced bowel movements.

Serious or Rare Side Effects

• Clostridioides difficile infection: severe colitis requiring medical attention.
• Anaphylaxis: life‑threatening allergic reaction with rash, swelling, or breathing difficulty.
• Stevens‑Johnson syndrome: rare skin disorder with blistering and detachment.
• Elevated liver enzymes: indication of hepatic stress.
• Hypomagnesemia: low magnesium levels that may cause muscle cramps or arrhythmias.
• Increased risk of bone fractures: especially with long‑term use.

Before initiating therapy, consider the following precautions.

• Renal function assessment: adjust use in patients with severe renal impairment.
• Hepatic disease evaluation: monitor liver function in patients with existing liver conditions.
• Long‑term therapy monitoring: watch for potential bone density loss and magnesium deficiency.
• Hypersensitivity check: avoid in individuals with known allergy to omeprazole or other PPIs.
• Drug interaction review: assess concomitant medications that may alter omeprazole effectiveness.
• Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Omeprazole can affect the pharmacokinetics of several medicines.

Major Interactions (Avoid)

• Clopidogrel: reduced conversion to its active metabolite, decreasing antiplatelet effect.
• Atazanavir: decreased absorption leading to sub‑therapeutic antiviral levels.
• HIV protease inhibitors (e.g., ritonavir): lowered plasma concentrations, compromising HIV control.

Moderate Interactions (Monitor Closely)

• Digoxin: increased serum levels may require dosage adjustment.
• Phenytoin: reduced plasma concentration, potentially lowering seizure control.
• Vitamin B12: decreased absorption with prolonged use, consider supplementation.